This site is intended for healthcare professionals
News

Complete Response Letter from FDA for NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.- Ardelyx.

Read time: 1 mins
Last updated:1st Aug 2021
Published:31st Jul 2021
Ardelyx, Inc. announced that it has received a Complete Response Letter (CRL) from the FDA regarding the company's New Drug Application (NDA) for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Condition: Hyperphosphataemia
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest